| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 8 | 2026 | 304 | 2.240 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2017 | 79 | 0.990 |
Why?
|
| Phenylthiohydantoin | 1 | 2026 | 8 | 0.970 |
Why?
|
| Kidney Neoplasms | 7 | 2017 | 103 | 0.970 |
Why?
|
| Benzamides | 1 | 2026 | 40 | 0.950 |
Why?
|
| Urologic Neoplasms | 3 | 2021 | 13 | 0.860 |
Why?
|
| Cystectomy | 4 | 2017 | 104 | 0.850 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2025 | 166 | 0.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 433 | 0.730 |
Why?
|
| Urologists | 2 | 2019 | 8 | 0.700 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2020 | 11 | 0.690 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 6 | 0.600 |
Why?
|
| Biopsy | 2 | 2017 | 208 | 0.580 |
Why?
|
| Male | 28 | 2026 | 14056 | 0.570 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 9 | 0.540 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 20 | 0.530 |
Why?
|
| Insurance Coverage | 1 | 2017 | 31 | 0.530 |
Why?
|
| Insurance, Health | 1 | 2017 | 51 | 0.530 |
Why?
|
| Humans | 42 | 2026 | 29089 | 0.530 |
Why?
|
| Prostatectomy | 2 | 2026 | 90 | 0.520 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 12 | 0.480 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2015 | 5 | 0.480 |
Why?
|
| Neoplasm Staging | 11 | 2017 | 480 | 0.470 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2015 | 4 | 0.460 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 71 | 0.440 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2025 | 56 | 0.440 |
Why?
|
| Aged | 15 | 2026 | 5627 | 0.440 |
Why?
|
| Algorithms | 1 | 2017 | 432 | 0.440 |
Why?
|
| Thymus Neoplasms | 4 | 2014 | 8 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 165 | 0.420 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 156 | 0.420 |
Why?
|
| Middle Aged | 16 | 2026 | 7458 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 305 | 0.390 |
Why?
|
| Prostate-Specific Antigen | 2 | 2024 | 54 | 0.320 |
Why?
|
| Urologic Diseases | 1 | 2010 | 6 | 0.320 |
Why?
|
| Radiation Dosage | 1 | 2010 | 54 | 0.320 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2014 | 72 | 0.310 |
Why?
|
| Urology | 2 | 2019 | 30 | 0.280 |
Why?
|
| Female | 20 | 2025 | 15747 | 0.280 |
Why?
|
| Prospective Studies | 4 | 2026 | 1286 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 80 | 0.260 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 31 | 0.260 |
Why?
|
| Nitriles | 1 | 2026 | 38 | 0.240 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2026 | 32 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2026 | 118 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 2070 | 0.230 |
Why?
|
| Triage | 1 | 2025 | 34 | 0.230 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 138 | 0.220 |
Why?
|
| Adult | 10 | 2024 | 8081 | 0.220 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2003 | 19 | 0.210 |
Why?
|
| Placenta | 1 | 2024 | 78 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 681 | 0.210 |
Why?
|
| Retrospective Studies | 9 | 2017 | 2651 | 0.210 |
Why?
|
| Sex Characteristics | 1 | 2024 | 175 | 0.200 |
Why?
|
| Smartphone | 1 | 2024 | 80 | 0.200 |
Why?
|
| Nephrectomy | 3 | 2014 | 48 | 0.200 |
Why?
|
| Mobile Applications | 1 | 2024 | 82 | 0.200 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 73 | 0.200 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 159 | 0.200 |
Why?
|
| Gram-Negative Bacteria | 1 | 2003 | 62 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 686 | 0.190 |
Why?
|
| Young Adult | 4 | 2017 | 2856 | 0.180 |
Why?
|
| Risk Factors | 5 | 2016 | 2138 | 0.170 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 4 | 0.170 |
Why?
|
| Health Planning | 1 | 2001 | 7 | 0.170 |
Why?
|
| Oncologists | 1 | 2021 | 15 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 312 | 0.170 |
Why?
|
| Smoking Prevention | 1 | 2001 | 90 | 0.160 |
Why?
|
| Minority Health | 1 | 2019 | 5 | 0.150 |
Why?
|
| Child | 3 | 2015 | 2341 | 0.150 |
Why?
|
| Rural Health Services | 1 | 2019 | 27 | 0.150 |
Why?
|
| Health Promotion | 1 | 2001 | 180 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2019 | 98 | 0.150 |
Why?
|
| Disease Progression | 2 | 2017 | 481 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 538 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 151 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2017 | 69 | 0.140 |
Why?
|
| Prognosis | 7 | 2015 | 815 | 0.140 |
Why?
|
| Obesity | 1 | 2024 | 705 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 303 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 155 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 165 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 221 | 0.140 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 9 | 0.140 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Receptors, GABA-A | 1 | 2017 | 18 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 19 | 0.140 |
Why?
|
| Research Report | 1 | 2017 | 23 | 0.130 |
Why?
|
| Checklist | 1 | 2017 | 22 | 0.130 |
Why?
|
| Mutation | 3 | 2017 | 873 | 0.130 |
Why?
|
| Leiomyomatosis | 1 | 2017 | 2 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2017 | 9 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2025 | 631 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 557 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2017 | 130 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 80 | 0.120 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 81 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2016 | 16 | 0.120 |
Why?
|
| Genetic Counseling | 1 | 2015 | 15 | 0.120 |
Why?
|
| Ultrasonic Therapy | 1 | 2015 | 4 | 0.120 |
Why?
|
| Body Temperature | 1 | 2015 | 30 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 398 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2016 | 90 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2016 | 2430 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 147 | 0.110 |
Why?
|
| Cisplatin | 1 | 2016 | 186 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 14 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 122 | 0.110 |
Why?
|
| Adolescent | 3 | 2015 | 3239 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 26 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 40 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2017 | 263 | 0.100 |
Why?
|
| Vaccination | 1 | 2016 | 213 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 77 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 51 | 0.100 |
Why?
|
| Oklahoma | 1 | 2017 | 1062 | 0.100 |
Why?
|
| Dyskeratosis Congenita | 1 | 2013 | 1 | 0.100 |
Why?
|
| Microcephaly | 1 | 2013 | 8 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 6 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 53 | 0.100 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 32 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2003 | 29 | 0.100 |
Why?
|
| Intellectual Disability | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2017 | 902 | 0.100 |
Why?
|
| DNA Helicases | 1 | 2013 | 54 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 7 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 249 | 0.090 |
Why?
|
| Infant | 1 | 2015 | 1062 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2015 | 1207 | 0.090 |
Why?
|
| United States | 4 | 2019 | 2258 | 0.090 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2011 | 4 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 645 | 0.080 |
Why?
|
| Malnutrition | 1 | 2011 | 31 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2011 | 80 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2016 | 288 | 0.080 |
Why?
|
| Survival Rate | 4 | 2012 | 433 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 20 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 360 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 226 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 607 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 289 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 468 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 482 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 1619 | 0.060 |
Why?
|
| Jews | 2 | 2016 | 7 | 0.060 |
Why?
|
| Genome, Human | 2 | 2016 | 70 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2003 | 17 | 0.050 |
Why?
|
| Tennessee | 2 | 2014 | 27 | 0.050 |
Why?
|
| Lipids | 1 | 2024 | 220 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 612 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 99 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 465 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 413 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 415 | 0.050 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 118 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 268 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2001 | 7 | 0.040 |
Why?
|
| Telemedicine | 1 | 2024 | 214 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 194 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2001 | 87 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2003 | 340 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2001 | 49 | 0.040 |
Why?
|
| Research | 1 | 2001 | 93 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1261 | 0.040 |
Why?
|
| Animals | 2 | 2024 | 10758 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2019 | 5 | 0.040 |
Why?
|
| Sample Size | 1 | 2019 | 17 | 0.040 |
Why?
|
| Informed Consent | 1 | 2019 | 26 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 249 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2017 | 100 | 0.030 |
Why?
|
| American Cancer Society | 1 | 2017 | 4 | 0.030 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 4 | 0.030 |
Why?
|
| Smoking | 1 | 2001 | 480 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 314 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 55 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 93 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 211 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 1 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 54 | 0.030 |
Why?
|
| Thermometers | 1 | 2015 | 1 | 0.030 |
Why?
|
| Heating | 1 | 2015 | 6 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 108 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 50 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 271 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 237 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 139 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 18 | 0.030 |
Why?
|
| Neoplasms | 1 | 2024 | 882 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 289 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 218 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 108 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 128 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 134 | 0.030 |
Why?
|
| Mice | 1 | 2024 | 4846 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 461 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 239 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 827 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 126 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 6 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 39 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2013 | 21 | 0.030 |
Why?
|
| Sutures | 1 | 2013 | 15 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 36 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 328 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 88 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 148 | 0.020 |
Why?
|
| Telomerase | 1 | 2013 | 38 | 0.020 |
Why?
|
| Telomere | 1 | 2013 | 36 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 77 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1057 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 688 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 15 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 36 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 1483 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 191 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 236 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 84 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 1033 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 416 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 787 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 2003 | 7 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2003 | 35 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2003 | 34 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 40 | 0.010 |
Why?
|
| Cysteine | 1 | 2003 | 68 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 126 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 90 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 128 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 271 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 170 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 259 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 79 | 0.010 |
Why?
|
| Temperature | 1 | 2003 | 213 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2003 | 102 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 256 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 486 | 0.010 |
Why?
|